Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesomiR 1: TargomiRs in MPM and NSCLC
NCT02369198Phase 1Completed
- Sponsor
- Asbestos Diseases Research Institute
- Start
- Sep 2014
- Primary completion
- Jan 2017
- Modality
- Antisense DNA, Gene Editing, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TargomiRs in malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC), sponsored by Asbestos Diseases Research Institute. Primary endpoints: Maximum Tolerated Dose at 18 months, Dose Limiting Toxicities at 2 weeks and 2 more. Started Sep 2014; status: completed.
02
Drugs
TargomiRs
03
Conditions
malignant pleural mesothelioma (MPM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02369198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369198.